Clinical Trial Update: A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC [Phase 3]

View source ↗

Summary

A Phase 3 study comparing ganetespib plus docetaxel versus docetaxel alone in advanced non-small cell lung cancer was terminated, with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Ganetespib (ganetespib)

Snippet

Sponsor: Synta Pharmaceuticals Corp. | Conditions: Non-Small-Cell Lung Adenocarcinoma, Non-small Cell Lung Cancer Stage IIIB | Phase 3 | Status: TERMINATED | Results posted: 2016-07-01